Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for ...

Last week, BioVie announced a significant milestone: a Notice of Allowance from the Japan Patent Office for its application regarding a novel liquid formulation of terlipressin. This formulation, ...

With only one approved treatment currently available ... Over time, this can progress to fibrosis and cirrhosis, resulting in ...

Researchers at the University of Missouri found that diet and exercise can significantly improve liver disease caused by too ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Blocking the enzyme ACMSD can significantly reduce damage caused by metabolic liver disease according to a new study.

A New 3D Bioprinted Model Offers a Novel Tool to Study Common Liver Disease, and Perhaps Find an Effective Treatment Jan. 23, 2024 — Metabolic dysfunction--associated steatohepatitis or MASH ...

Genflow Biosciences PLC on Tuesday said it has secured EUR4 million in funding from the Wallonia region in Belgium, to support its gene therapy development work. The London-based biotechnology company ...